Protalix BioTherapeutics Net Income 2006-2021 | PLX

Protalix BioTherapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Protalix BioTherapeutics Annual Net Income
(Millions of US $)
2020 $-7
2019 $-18
2018 $-26
2017 $-83
2016 $-29
2015 $58
2014 $-30
2013 $-28
2012 $-12
2011 $-37
2010 $-29
2009 $-31
2008 $-22
2007 $-32
2006 $-9
2005 $-6
Protalix BioTherapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-11
2021-03-31 $-5
2020-12-31 $0
2020-09-30 $-4
2020-06-30 $-4
2020-03-31 $2
2019-12-31 $0
2019-09-30 $-4
2019-06-30 $-8
2019-03-31 $-7
2018-12-31 $-5
2018-09-30 $-5
2018-06-30 $-8
2018-03-31 $-7
2017-12-31 $-13
2017-09-30 $-11
2017-06-30 $0
2017-03-31 $-59
2016-12-31 $-3
2016-09-30 $-7
2016-06-30 $-11
2016-03-31 $-9
2015-12-31 $73
2015-09-30 $-4
2015-06-30 $-5
2015-03-31 $-6
2014-12-31 $-8
2014-09-30 $-8
2014-06-30 $-6
2014-03-31 $-7
2013-12-31 $-11
2013-09-30 $-6
2013-06-30 $-7
2013-03-31 $-4
2012-12-31 $-10
2012-09-30 $-5
2012-06-30 $10
2012-03-31 $-6
2011-12-31 $-9
2011-09-30 $-9
2011-06-30 $-14
2011-03-31 $-5
2010-12-31 $-9
2010-09-30 $-2
2010-06-30 $-10
2010-03-31 $-8
2009-12-31 $-15
2009-09-30 $-6
2009-06-30 $-5
2009-03-31 $-5
2008-12-31 $-7
2008-09-30 $-6
2008-06-30 $-4
2008-03-31 $-5
2007-12-31 $-15
2007-09-30 $-5
2007-06-30 $-9
2007-03-31 $-3
2006-12-31 $-3
2006-09-30 $-2
2006-06-30 $-2
2006-03-31 $-2
2005-12-31 $-6
2005-09-30 $-0
2005-06-30 $-0
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.053B $0.063B
Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76